Medical Cannabis Shows Promise for Hypermobility-Related Chronic Pain

A new UK study tracks pain, sleep, and anxiety outcomes over 18 months.

A new study from the UK offers encouraging news for people living with hypermobility-related chronic pain. Researchers found that patients with hypermobility spectrum disorder (HSD) or hypermobile Ehlers-Danlos syndrome (hEDS) who were treated with cannabis-based medicinal products (CBMPs) reported meaningful improvements in pain, sleep quality, and anxiety. These connective tissue conditions, which cause joint instability and widespread chronic pain, are estimated to affect around 3% of the population — more commonly women — and are notoriously difficult to manage with conventional treatments.

The study, published in ACR Open Rheumatology, drew on data from the UK Medical Cannabis Registry — the largest real-world database of medical cannabis patients in the UK. Researchers followed 161 patients with hypermobility-associated chronic pain over an 18-month period, collecting validated, self-reported measures of pain, sleep, anxiety, and overall quality of life. Many of these patients had already tried conventional treatments without success — in fact, under UK law, cannabis can only be prescribed after licensed treatments have failed.

What the Study Found

Across the 18 months, patients reported statistically significant improvements in pain severity and interference, general health-related quality of life, sleep quality, and anxiety. Many improvements appeared within the first month of treatment and were largely sustained over the longer term. At the 18-month mark, depending on which pain measure was used, roughly one-fifth to one-quarter of patients reported a clinically significant reduction in pain — a meaningful result for a group whose pain had not responded to other options.

On safety, about 31% of participants reported one or more side effects. These were mostly mild to moderate — headache, fatigue, and lethargy were among the most common — and importantly, there were no life-threatening or disabling adverse events. The majority of patients reported no side effects at all.

Promising Evidence — With Important Context

It's worth being clear about what kind of study this is. It was a case series — an observational analysis of real-world patient data, not a randomized controlled trial. That means it can show an association between cannabis treatment and symptom improvement, but it cannot prove cause and effect. The study's own authors emphasize this, and call for rigorous randomized controlled trials to confirm how effective and safe CBMPs truly are for this group. It's also worth noting that several of the researchers are affiliated with a commercial medical cannabis clinic.

Even with those caveats, this research is genuinely valuable. It adds real-world evidence to a long-neglected area, and it lends weight to what many patients with chronic conditions have described from their own experience: that, used responsibly and under proper medical supervision, cannabis-based treatments can make a meaningful difference to daily life. For people living with the constant challenges of hypermobility-related pain, that's a welcome and hopeful step.

Reference: Dickinson M, Erridge S, Warner-Levy J, et al. UK Medical Cannabis Registry: An Analysis of Outcomes of Medical Cannabis Therapy for Hypermobility-Associated Chronic Pain. ACR Open Rheumatology, 2025;7(3):e70024. DOI: 10.1002/acr2.70024.

This article is for general information only and is not medical advice. Please consult a qualified healthcare professional before making any treatment decisions.